Raamsdonksveer, Netherlands / Potsdam, Germany, Wednesday 1 April 2026 – In the presence of the Mayor of the City of Potsdam, Noosha Aubel, the Dopharma Group and its fully owned subsidiary Ripac-Labor GmbH celebrated the topping-out ceremony for their new, state-of-the-art production facility for autogenous vaccines.
With this project, the company is laying the foundation for its long-term presence in the region. The production facility is specifically designed for the manufacturing of autogenous vaccines and is being developed at a time of significant regulatory evolution at both European and national levels. These changes aim to harmonize Good Manufacturing Practice (GMP) requirements for these specialized veterinary medicinal products across Europe.
Ahead of European legislation
Despite the EU legislation is not yet official, the Dopharma Group and Ripac-Labor remain committed to their responsibility. This means the continuation of investments in the future of autogenous vaccines, while consistently advancing this ambitious project.
‘The Dopharma Group firmly believes that autogenous vaccines will play a crucial role in livestock farming by safeguarding animal health’, emphasizes Wijnand de Bruijn, CEO Business of the Dopharma Group. ‘With this new production facility, we are setting benchmarks in quality and innovation. It will be among the most advanced facilities of its kind in Europe and will make a significant contribution to the sustainable development of the company’.
Commissioning planned for end of 2026
This investment project underlines the company’s commitment to innovation, global animal health, and future-oriented, sustainable agricultural production. Thanks to the proven fast-track approach of the general planner PBM gr.up GmbH, commissioning of the new production facility is scheduled already for the end of 2026.
For media inquiries, please contact: [email protected].
Media gallery
About Ripac-Labor GmbH
Ripac-Labor GmbH, a fully owned subsidiary of Dopharma International B.V., specializes in veterinary services and the production of autogenous vaccines for livestock. These customized vaccines provide targeted protection against farm-specific pathogens, offering a crucial tool for disease prevention and control. The expansion of Ripac-Labor’s production capabilities further strengthens the Dopharma group’s position in the European veterinary market.
The company currently employs almost 50 academic specialists, experienced laboratory technicians, and other well-trained staff.
About the Dopharma Group
Dopharma is a family-owned pharmaceutical company dedicated to producing and supplying high-quality veterinary pharmaceuticals for livestock since 1969. With 95% of its veterinary pharmaceuticals manufactured in-house at its GMP-certified production facilities, Dopharma ensures strict quality control and continuous innovation. The company’s mission is to provide smart, science-driven solutions that support the health and productivity of livestock worldwide.
